AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8943962 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 1145
Study 8943962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1145
Study 1850682 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (30 ng min‐1 kg‐1)
Number of subjects: 16
Study 1850682 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine bicycle exercise
Number of subjects: 16
Study 1850682 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 16
Study 31438936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Cycle Deliberate Practice (RCDP)
Number of subjects: 0
Study 31438936 — intervention group
Group type: COMPARATOR
Intervention: Traditional simulation
Number of subjects: 0
Study 27351077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 100
Study 27351077 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 100
Study 27351077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 100
Study 25758472 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (150mg) administered twice weekly for 4 weeks, then once weekly for 32 weeks
Number of subjects: 34
Study 25758472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 25758472 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept
Number of subjects: 34
Study 23680243 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 34
Study 23680243 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 34
Study 21829595 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance dose pegylated-IFNα for an additional 3.5 years
Number of subjects: 29
Study 21829595 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy group
Number of subjects: 29
Study 19735787 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent music during gait tasks in PD patients
Number of subjects: 20
Study 19735787 — intervention group
Group type: COMPARATOR
Intervention: Concurrent music during gait tasks in control subjects
Number of subjects: 20
Study 19735787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task with concurrent music in PD patients
Number of subjects: 20
Study 19735787 — intervention group
Group type: COMPARATOR
Intervention: Dual-task with concurrent music in control subjects
Number of subjects: 20
Study 17826646 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (LS)
Number of subjects: 50
Study 17826646 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 15195496 — intervention group
Group type: EXPERIMENTAL
Intervention: Men instructed to wash hands before masturbation
Number of subjects: 93
Study 15195496 — intervention group
Group type: COMPARATOR
Intervention: Men not instructed to wash hands before masturbation
Number of subjects: 93
Study 15195496 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect of semen contamination on fertilization rate and embryo quality
Number of subjects: 93
Study 11477282 — intervention group
Group type: EXPERIMENTAL
Intervention: Active physiotherapy
Number of subjects: 148
Study 11477282 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle reconditioning on training devices
Number of subjects: 148
Study 11477282 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impact aerobics
Number of subjects: 148
Study 9713038 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium enriched yeast (4.8 mg containing 5 micrograms selenium daily)
Number of subjects: 36
Study 9713038 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented group
Number of subjects: 36
Study 7985832 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin flushing three times/day by hospital IV team (Group A)
Number of subjects: 40
Study 7985832 — intervention group
Group type: COMPARATOR
Intervention: Heparin 1 mL of 2500 units in each lumen after dialysis three times/week by dialysis nurses (Group B)
Number of subjects: 40
Study 2525101 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 800 micrograms twice daily via a Nebuhaler for 16 weeks
Number of subjects: 10
Study 2525101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (healthy volunteers and sarcoid patients)
Number of subjects: 10
Study 30943553 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day low-residue diet (LRD)
Number of subjects: 390
Study 30943553 — intervention group
Group type: COMPARATOR
Intervention: 1-day low-residue diet (LRD)
Number of subjects: 390
Study 27441549 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management program (IY TCM)
Number of subjects: 1818
Study 27441549 — intervention group
Group type: COMPARATOR
Intervention: Control, business as usual condition
Number of subjects: 1818
Study 26563011 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 100
Study 26563011 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 100
Study 26563011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 100
Study 26563011 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 100
Study 23572200 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid intake
Number of subjects: 4680
Study 23572200 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid from vegetable sources
Number of subjects: 4680
Study 21242741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1200 mg administered once daily at 5 pm; dose adjustments to 600 or 1800 mg were permitted based on investigator judgment.
Number of subjects: 573
Study 18506025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus pemetrexed (n = 862)
Number of subjects: 1725
Study 18506025 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine (n = 863)
Number of subjects: 1725
Study 18506025 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine (n = 473)
Number of subjects: 1725
Study 18506025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus pemetrexed
Number of subjects: 1725
Study 18506025 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine
Number of subjects: 1725
Study 16228238 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy
Number of subjects: 182
Study 16228238 — intervention group
Group type: COMPARATOR
Intervention: Shunting
Number of subjects: 182
Study 12974680 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic fingerprinting of mutans streptococci strains
Number of subjects: 16
Study 10920309 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg danazol 3 times daily for 6 months
Number of subjects: 20
Study 10920309 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprolide depot every 28 days for 6 months
Number of subjects: 20
Study 10920309 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 women without endometriosis)
Number of subjects: 20
Study 10920309 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment (3 months after treatment)
Number of subjects: 20
Study 8604441 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic Study
Number of subjects: 0
Study 8604441 — intervention group
Group type: COMPARATOR
Intervention: Holter Monitoring
Number of subjects: 0
Study 8604441 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 8604441 — intervention group
Group type: COMPARATOR
Intervention: Other Drugs
Number of subjects: 0
Study 1575287 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (20 mg/kg or 40 mg/kg body weight)
Number of subjects: 322
Study 3907790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg . kg‐1)
Number of subjects: 62
Study 3907790 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (4 mg . kg‐1)
Number of subjects: 62
Study 3907790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ketamine and Thiopentone)
Number of subjects: 62
Study 30213882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide coadministered with regular human insulin (fixed ratio 9 μg/unit)
Number of subjects: 0
Study 30213882 — intervention group
Group type: COMPARATOR
Intervention: Placebo coadministered with regular human insulin
Number of subjects: 0
Study 25670810 — intervention group
Group type: EXPERIMENTAL
Intervention: Train‐Colonoscopy‐Leaders (TCLs) programme (assessment, hands‐on training, post‐training feedback)
Number of subjects: 24
Study 25670810 — intervention group
Group type: COMPARATOR
Intervention: Feedback only (individual quality measures)
Number of subjects: 24
Study 25023385 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional hand splint only (n=15)
Number of subjects: 30
Study 25023385 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional hand splint combined with task-specific training (n=15)
Number of subjects: 30
Study 25023385 — intervention group
Group type: COMPARATOR
Intervention: Task-specific training only (n=15)
Number of subjects: 30
Study 22726710 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Time intervention
Number of subjects: 7
Study 20042769 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (2 g/d)
Number of subjects: 108
Study 20042769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 108
Study 18285347 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinical pathway (12 visits over 6 weeks)
Number of subjects: 91
Study 15809478 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI SPECT at 5 days after clinical deterioration
Number of subjects: 32
Study 15809478 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI SPECT at 10 days after clinical deterioration
Number of subjects: 32
Study 15809478 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI SPECT at 30 days after clinical deterioration
Number of subjects: 32
Study 15809478 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI SPECT at 2 days after clinical deterioration
Number of subjects: 32
Study 15809478 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI SPECT at 30 days after clinical deterioration (second examination for group 1)
Number of subjects: 32
Study 15809478 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 99mTc‐MIBI indices among the 4 groups
Number of subjects: 32
Study 14564683 — intervention group
Group type: EXPERIMENTAL
Intervention: l-thyroxine therapy (1.8 mug/kg daily)
Number of subjects: 31
Study 14564683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 31
Study 14564683 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 10850524 — intervention group
Group type: EXPERIMENTAL
Intervention: gatifloxacin 400 mg/day orally
Number of subjects: 48
Study 10850524 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin 500 mg twice/day orally
Number of subjects: 48
Study 10850524 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 8792382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 100 micrograms once daily (od)
Number of subjects: 535
Study 8792382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 100 micrograms twice daily (bd)
Number of subjects: 535
Study 8792382 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDPANS) 200 micrograms bd
Number of subjects: 535
Study 8792382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms od
Number of subjects: 535
Study 8792382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study 1636712 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (6 mg/kg)
Number of subjects: 14
Study 1636712 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 14
Study 6533789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (Vitamin C) 1 gram administered randomly to healthy young people for two months
Number of subjects: 2
Study 6533789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (Vitamin C) 1 gram administered to healthy older people for six to twelve months
Number of subjects: 2
Study 6533789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (Vitamin C) 1 gram per day administered throughout the year
Number of subjects: 2
Study 6533789 — intervention group
Group type: COMPARATOR
Intervention: Seasonal observations on a mixed age group of healthy people (aged 38 +/- 12 years)
Number of subjects: 2
Study 31209718 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical medication review (CMR)
Number of subjects: 216
Study 31209718 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216
Study 29114770 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant-directed speech (IDS)
Number of subjects: 46
Study 29114770 — intervention group
Group type: COMPARATOR
Intervention: Adult-directed speech (ADS)
Number of subjects: 46
Study 29114770 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant-directed speech (IDS) preference quotient
Number of subjects: 46
Study 25841956 — intervention group
Group type: EXPERIMENTAL
Intervention: TF in rotary motion
Number of subjects: 30
Study 25841956 — intervention group
Group type: EXPERIMENTAL
Intervention: TF Adaptive
Number of subjects: 30
Study 25841956 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Universal
Number of subjects: 30
Study 25841956 — intervention group
Group type: EXPERIMENTAL
Intervention: TF
Number of subjects: 30
Study 24260894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicarbamine
Number of subjects: 2
Study 24260894 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 2
Study 21860562 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K + vitamin D + calcium supplement (15 mg of vitamin K2 three times daily, 400 IU of vitamin D once a day, and 315 mg of calcium twice daily)
Number of subjects: 78
Study 21860562 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K + vitamin D + calcium supplement
Number of subjects: 78
Study 21860562 — intervention group
Group type: COMPARATOR
Intervention: Control group (vitamin D + calcium supplement)
Number of subjects: 78
Study 19339136 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity condition
Number of subjects: 147
Study 19339136 — intervention group
Group type: COMPARATOR
Intervention: High-fidelity condition
Number of subjects: 147
Study 16352379 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (local anaesthetic cream)
Number of subjects: 13
Study 16352379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 14745753 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose MR angiography using diluted contrast medium injected at a rate of 1 mL/second
Number of subjects: 72
Study 14745753 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose MR angiography using diluted contrast medium injected at a rate of 0.5 mL/second
Number of subjects: 72
Study 14745753 — intervention group
Group type: COMPARATOR
Intervention: Full-dose MR angiography using original concentration injected at a rate of 1 mL/second
Number of subjects: 72
Study 14745753 — intervention group
Group type: COMPARATOR
Intervention: Full-dose MR angiography using original concentration injected at a rate of 0.5 mL/second
Number of subjects: 72
Study 11694767 — intervention group
Group type: EXPERIMENTAL
Intervention: Platin-based chemotherapy including new drugs (vinorelbine, gemcitabine, paclitaxel, docetaxel)
Number of subjects: 0
Study 11694767 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs in combination with platin-based chemotherapy
Number of subjects: 0
Study 11694767 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy
Number of subjects: 0
Study 11694767 — intervention group
Group type: COMPARATOR
Intervention: Non-platin-based combinations
Number of subjects: 0
Study 9778204 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline hydrochloride (started at 25 mg before bed, titrated to 75 mg/d or maximal tolerated dose)
Number of subjects: 214
Study 9778204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched to nortriptyline)
Number of subjects: 214
Study 9778204 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline hydrochloride
Number of subjects: 214
Study 8151049 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 506
Study 8151049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 3597656 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy
Number of subjects: 0
Study 3597656 — intervention group
Group type: COMPARATOR
Intervention: Partial mastectomy
Number of subjects: 0
Study 3597656 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 30318066 — intervention group
Group type: EXPERIMENTAL
Intervention: Volanesorsen sodium (antisense inhibitor of apolipoprotein C‐III)
Number of subjects: 66
Study 30318066 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 66
Study 30318066 — intervention group
Group type: COMPARATOR
Intervention: Fibrates
Number of subjects: 66
Study 30318066 — intervention group
Group type: COMPARATOR
Intervention: Fish oils
Number of subjects: 66
Study 30318066 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 66
Study 28133878 — intervention group
Group type: EXPERIMENTAL
Intervention: Acne RA-1,2
Number of subjects: 40
Study 28133878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26075317 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa booster using the new syringe presentation (dTpa-new)
Number of subjects: 671
Study 26075317 — intervention group
Group type: COMPARATOR
Intervention: dTpa booster using the previous syringe presentation (dTpa-previous)
Number of subjects: 671
Study 23095336 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged treadmill exercise
Number of subjects: 7
Study 21587143 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (65 mL fermented milk drink containing 6.5×10^9 CFU daily)
Number of subjects: 40
Study 17717533 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein hydrolysate (0.4 g kg(‐1) bw casein hydrolysate, PRO)
Number of subjects: 13
Study 17717533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study 17717533 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein hydrolysate (PRO)
Number of subjects: 13
Study 16837886 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E(2)
Number of subjects: 112
Study 16837886 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) with NETA
Number of subjects: 112
Study 16837886 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E(2)
Number of subjects: 112
Study 16837886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 14738630 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 2530
Study 14738630 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-converted cases)
Number of subjects: 2530
Study 10872641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol infusion (100 mg/dL)
Number of subjects: 10
Study 10872641 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water infusion
Number of subjects: 10
Study 9119421 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related changes in the brain (senile plaques and neurofibrillary tangles)
Number of subjects: 52
Study 9119421 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease cases studied
Number of subjects: 52
Study 9119421 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 52
Study 9119421 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid immunostaining
Number of subjects: 52
Study 8468875 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose monitor (BGM) intervention, finger stick test in triage area.
Number of subjects: 68
Study 8468875 — intervention group
Group type: COMPARATOR
Intervention: Control group, no finger stick test.
Number of subjects: 68
Study 2834482 — intervention group
Group type: EXPERIMENTAL
Intervention: CY 222 at 150 U/kg + 1,000 U/h
Number of subjects: 21
Study 2834482 — intervention group
Group type: EXPERIMENTAL
Intervention: CY 222 at 300 U/kg
Number of subjects: 21
Study 2834482 — intervention group
Group type: EXPERIMENTAL
Intervention: CY 222 at 200 U/kg and 250 U/kg (single-dose injection)
Number of subjects: 21
Study 2834482 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (SH)
Number of subjects: 21
Study 29273688 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 21
Study 29273688 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with FMD
Number of subjects: 21
Study 27671673 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG) implant
Number of subjects: 1328
Study 27671673 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 1328
Study 27671673 — intervention group
Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 1328
Study 24983797 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent exposure (CE)
Number of subjects: 57
Study 24983797 — intervention group
Group type: EXPERIMENTAL
Intervention: Varied exposure (VE)
Number of subjects: 57
Study 24983797 — intervention group
Group type: COMPARATOR
Intervention: Neutral control (NC)
Number of subjects: 57
Study 22296168 — intervention group
Group type: EXPERIMENTAL
Intervention: beer/no-go condition
Number of subjects: 57
Study 22296168 — intervention group
Group type: COMPARATOR
Intervention: beer/go condition
Number of subjects: 57
Study 21095492 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of fluoxetine hydrochloride 20 mg
Number of subjects: 24
Study 21095492 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of fluoxetine hydrochloride 20 mg
Number of subjects: 24
Study 21095492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24